[ad_1]
Optimism for the results of the first two phases.
The entire planet is watching with anxiety the dramatic struggle of scientists for discovery and Friday against the coronavirus pandemic.
Johnson & Johnson announced today that it is launching trials, as the Phase 1 and Phase 2 study showed that the safety profile and immunogenicity support further development.
The phase 3 study will evaluate the safety and efficacy of the vaccine in a sample of up to 60,000 adults, with an adequate representation of people over 60, the company said.
“With the candidate vaccine in the third phase trials, we are one step closer to finding a solution for the COVID-19 disease.”said Mathai Mammen, head of research and development at Janssen. “We use a highly scientific and evidence-based approach to select the specific vaccine.”he added.
Since announcements were made that the Johnson & Johnson vaccine is moving forward, online commerce has increased 2.5%.
AstraZeneca Vaccine Clinical Trials and Oxford University on the other side of the Atlantic have frozen, and the US media hints that they will not start immediately. The New York Times, no, they talk about scientific concerns about neurological side effects vaccine and quotes Mark Slifka, a vaccine specialist at Oregon Health and Science University, as saying: “If there are already two cases, then the plan starts to get dangerous.” If a third case of neurological disorder occurs in the test group, then the final titers for the specific vaccine may drop. “
Δeither all the latest news from Greece and the world, as it happens, on Newsbomb.gr
Read also:
Coronavirus: Hospital SOS – ICUs manufactured in Sotiria and Nikaia State Hospital
